Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference
September 18 2017 - 9:02AM
Business Wire
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company
focused on the discovery, development and commercialization of
immunotherapy products, today announced that Anthony Lombardo,
interim chief executive officer, will present a company overview at
the Cantor Fitzgerald Global Healthcare Conference being held Sept.
25-27, 2017 in New York. The conference will feature more than 200
innovative industry leaders from public and private companies for
an in-depth discussion of the developments and trends shaping
biotechnology, specialty pharmaceuticals, medical technology,
healthcare facilities and services, and life sciences tools and
diagnostics.
Event: Cantor Fitzgerald Global Healthcare Conference
Presentation Date: Monday, Sept. 25, 2017
Presentation Time: 8:30 a.m. EDT
Location: InterContinental New York Barclay Hotel, New
York
Lombardo has nearly 30 years of leadership experience in the
life sciences industry with a proven track record of helping global
companies achieve significant growth. Honored by the American
College of Radiology and the Society of Abdominal Radiology for his
years of service to the clinical community, he currently serves as
chairman of the advisory board of Morristown Medical Center, a part
of Atlantic Health System Hospitals.
About Advaxis, Inc.
Advaxis, Inc., located in Princeton N.J., is a late-stage
biotechnology company focused on the discovery, development and
commercialization of proprietary Lm-based antigen delivery
products. These immunotherapies are based on a platform technology
that utilizes live attenuated Listeria monocytogenes (Lm)
bioengineered to secrete antigen/adjuvant fusion proteins. These
Lm-based strains are believed to be a significant advancement in
immunotherapy as they integrate multiple functions into a single
immunotherapy as they access and direct antigen presenting cells to
stimulate anti-tumor T-cell immunity, stimulate and activate the
immune system with the equivalent of multiple adjuvants, and
simultaneously reduce tumor protection in the tumor
microenvironment to enable the T-cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and pre-clinical
development: HPV-associated cancers, prostate cancer, neoantigen
therapy and hotspot mutation therapy.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2016, which is available at http://www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law.
You are cautioned not to place undue reliance on any
forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170918005383/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorMedia:Stern Strategy GroupBrian
Hyland, 908-325-3891Bhyland@sternstrategy.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024